Lido Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Lido Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-33,469	Closed	-$1.51M	–	1535
2024 Q3	$1.51M	Sell	33,469 -3,992	-11%	-$178K	0.01%	556
2024 Q2	$1.56M	Sell	37,461 -32,682	-47%	-$1.37M	0.01%	513
2024 Q1	$3.19M	Sell	70,143 -4,810	-6%	-$219K	0.02%	345
2023 Q4	$3.47M	Sell	74,953 -13,858	-16%	-$565K	0.02%	314
2023 Q3	$3.61M	Buy	88,811 +6,447	+8%	+$294K	0.03%	287
2023 Q2	$3.99M	Buy	82,364 +1,372	+2%	+$68.6K	0.03%	254
2023 Q1	$3.99M	Buy	80,992 +471	+0.6%	+$24.2K	0.04%	235
2022 Q4	$4.07M	Buy	+80,521	New	+$4.15M	0.05%	193

Other funds holding GNOM

OCM

One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $73.7B AUM 53.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.11B AUM 20.67% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Lido Advisors's GNOM Position: Q4 2024 in Review

Lido Advisors sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q4 2024, closing a stake of 33,469 shares — an estimated $1.51M sold.

Lido Advisors first reported a position in GNOM in Q4 2022 and held it in 8 quarters. The position peaked at $4.07M in Q4 2022. 68 funds tracked by Wall St. Rank hold GNOM as of Q4 2024.

Lido Advisors reported no remaining Global X Genomics & Biotechnology ETF position as of Q4 2024 after selling out during the quarter.
Lido Advisors sold 33,469 Global X Genomics & Biotechnology ETF shares in Q4 2024, an estimated $1.51M.
Lido Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q4 2022 and held it in 8 quarters.
Lido Advisors's Global X Genomics & Biotechnology ETF position peaked at $4.07M in Q4 2022.
68 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q4 2024.

Based on Lido Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.